The estimated Net Worth of Patrick J. O Mara is at least $163 Tisíc dollars as of 15 April 2016. Mr Mara owns over 5,000 units of Cymabay Therapeutics Inc stock worth over $163,115 and over the last 9 years he sold CBAY stock worth over $0.
Mr has made over 2 trades of the Cymabay Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CBAY stock worth $8,200 on 15 April 2016.
The largest trade he's ever made was buying 5,000 units of Cymabay Therapeutics Inc stock on 15 April 2016 worth over $8,200. On average, Mr trades about 1,250 units every 0 days since 2016. As of 15 April 2016 he still owns at least 5,022 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr Mara stock trades at the bottom of the page.
Patrick J. O'Mara is the Sr. VP of Bus. Devel. at Cymabay Therapeutics Inc.
Mr Mara is 60, he's been the Sr. VP of Bus. Devel. of Cymabay Therapeutics Inc since . There are 3 older and 12 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
Patrick's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD., SUITE 130, NEWARK, CA, 94560.
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster a Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: